share_log

Lyell Immunopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-James Tananbaum (“Tananbaum”)(5.3%),Foresite Capital Fund IV, L.P. (“FCF IV”)(3.2%), etc.

Lyell Immunopharma | SC 13G:超过5%持股股东披露文件-James Tananbaum (“Tananbaum”)(5.3%),Foresite Capital Fund IV, L.P. (“FCF IV”)(3.2%)等

美股SEC公告 ·  10/31 18:00
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息